Sasidhar Guthikonda, MD
Interventional Cardiology · Humacao, PRNPI 1851595367
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $463 and has fallen 80.7% since, to $89 in 2025. That places this record below the midpoint for interventional cardiology clinicians in PR, where the typical reported total is $12,032.
Across 76 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$181
- Pfizer$128
- Boehringer Ingelheim$128
- AstraZeneca$112
- Amgen$108
- Inari Medical, Inc.$102
- plus $758 from 17 others
What the payments were for
- Food & beverage$1,517100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 10 | $181 |
| Pfizer | 7 | $128 |
| Boehringer Ingelheim | 5 | $128 |
| AstraZeneca | 5 | $112 |
| Amgen | 6 | $108 |
| Inari Medical, Inc. | 3 | $102 |
| Merck | 3 | $99 |
| E.r. Squibb & Sons, L.L.C. | 6 | $98 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $98 |
| Medtronic(2 entities) | 4 | $81 |
| Johnson & Johnson | 5 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $69 |
| Edwards Lifesciences | 2 | $46 |
| Bayer | 2 | $35 |
| Abbott | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $21 |
| Kls-martin L.p. | 1 | $20 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| Angiodynamics, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Cordis US CORP. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Terumo Medical Corporation | 1 | $11 |
How this compares
$1,517 in reported general payments places this provider in the 10th percentile of 39 interventional cardiology providers in Puerto Rico.
See all interventional cardiology providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 261 | $306,610 |
| EntrestoSacubitril/Valsartan | 115 | $120,981 |
| XareltoRivaroxaban | 53 | $69,406 |
| Repatha SureclickEvolocumab | 19 | $24,657 |
| BrilintaTicagrelor | 21 | $18,825 |
| VascepaIcosapent Ethyl | 14 | $8,281 |
| FarxigaDapagliflozin Propanediol | 12 | $6,753 |
| Prasugrel Hcl | 55 | $6,124 |
| ClopidogrelClopidogrel Bisulfate | 444 | $4,984 |
| Atorvastatin Calcium | 568 | $4,820 |
| Rosuvastatin Calcium | 385 | $4,308 |
| Metoprolol Succinate | 295 | $4,291 |
| Nifedipine ErNifedipine | 49 | $2,619 |
| Flecainide Acetate | 38 | $2,461 |
| Metoprolol Tartrate | 247 | $1,852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $128 | $306,610261 claims |
| NovartisEntresto | $181 | $120,981115 claims |
| Johnson & JohnsonXarelto | $79 | $69,40653 claims |
| AstraZenecaBrilinta, Farxiga | $112 | $25,57833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 39 interventional cardiology providers in Puerto Rico.
Other interventional cardiology in Humacao
- Damian Grovas AbadSan Juan$498K
- Eric Carro JimenezSan Juan$416K
- Hector Martinez GonzalezMayaguez$261K
- Alejandro Lopez MasPonce$142K
- Ricardo SantiagoManati$131K
- Edwin I Perez MarreroSan Juan$129K
- Pedro Colon HernandezCaguas$128K
- Enrique Hernandez VilaPonce$44K
- Ismael Ortiz-CartagenaBayamon$40K
- Bayoan Ramos ParraCaguas$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.